CJ-007

CJ-007 is a first-in-class, small molecule androgen receptor (AR) inhibitor developed by Guangdong Xijie Pharmaceutical. It is specifically engineered to address the limitations of current AR-targeted therapies, such as enzalutamide and abiraterone, by targeting not only wild-type AR but also AR gene amplifications, point mutations (including F877L and T878A), and AR splice variants (such as AR-V7). These alterations are common drivers of resistance in patients with metastatic castration-resistant prostate cancer (mCRPC). By effectively inhibiting these resistant forms of the receptor, CJ-007 aims to restore sensitivity to hormonal therapy and provide a new treatment option for patients who have progressed on standard-of-care AR signaling inhibitors. The drug is currently undergoing Phase 1 clinical evaluation in China.